Skip to main content
    L

    Lantern Pharma Inc (LTRN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.36
    -0.02 (-6.17%)

    Market Cap: $5.81M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Lantern Pharma Inc (LTRN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Lantern Pharma (LTRN) has a market cap of $5.81M. Its share count is up 24.67% from a year earlier. It holds $7.61M more cash than debt, 130.96% of its market cap.

    Total Valuation

    Market Cap$5.81M
    Latest price (Nov 17, 2026)$0.36

    Key Dates

    The next earnings report is expected on Nov 17, 2026, covering the quarter ending Sep 30, 2026.

    Next Earnings DateNov 17, 2026 (expected)
    Last Earnings DateAug 14, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 8.71% in the quarter ended Sep 30, 2026 and grew 12.02% a year over 2 years.

    Shares Outstanding13.51M
    Shares Change (YoY)+24.67%
    Shares Change (QoQ)+8.71%
    Share Count Growth (2Y CAGR)+12.02%

    Price Statistics

    The stock is down 89.20% over 52 weeks and trades 61.29% below its 50-day average.

    Beta (1Y)3.04
    52-Week Change-89.20%
    1-Month Change-43.08%
    3-Month Change-85.34%
    6-Month Change-88.19%
    5-Year Change-93.53%
    Total Return (1Y)-89.20%
    Total Return (3Y CAGR)-55.08%
    Total Return (5Y CAGR)-46.82%
    Max Drawdown (1Y)-91.25%
    Max Drawdown (3Y)-96.57%
    Sharpe Ratio (1Y)-1.92
    Correlation with SPY (1Y)0.37
    50-Day Average$0.93
    200-Day Average$2.29
    52-Week Range$0.38 to $4.34
    RSI (14 Days)23.9
    Average Volume (20 Days)182.64K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.49x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio1.49x
    Quick Ratio1.49x
    Debt / Equity0.01x

    Returns and Efficiency

    Return on invested capital is -778.39% over the last 12 months, against a 5-year average of -71.79%.

    Return on Equity (ROE)-977.05%
    Return on Assets (ROA)-161.64%
    Return on Invested Capital (ROIC)-778.39%
    ROE (5Y Average)-88.36%
    ROA (5Y Average)-62.78%
    ROIC (5Y Average)-71.79%

    Scores

    LTRN has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $0 over the last 12 months is down 100.00% from the 12 months before.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit$4.10K
    Operating Income-$16.49M
    Pretax Income-$13.79M
    Net Income-$13.78M
    Reported EPS (TTM)-$1.33

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 16.55% of the $8.52M in total assets.

    Cash and Equivalents$7.62M
    Total Debt$7.11K
    Net Cash$7.61M
    Net Cash Per Share$0.56
    Working Capital$2.76M
    Shareholder Equity$1.41M
    Book Value Per Share$0.10
    Total Assets$8.52M
    Total Liabilities$7.11M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$12.85M
    FCF Per Share-$0.86
    Depreciation and Amortization$40.68K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-60.21%
    Tangible Book Per Share Growth (2Y CAGR)-60.21%

    Revenue and profit by year

    Dividends and Yields

    LTRN does not pay a dividend.

    Buyback Yield-87.05%
    Shareholder Yield-87.05%

    Peer Position

    Against 4 similar companies, LTRN has the 4th highest ROIC.

    ROIC-778.39% vs -202.00% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -99.32% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About LTRN

    What is LTRN's market cap?

    Lantern Pharma has a market cap of $5.81M.

    How many shares of LTRN are outstanding?

    Lantern Pharma has 13.51M shares outstanding. The count is up 24.67% from a year earlier.

    Does LTRN pay a dividend?

    No. Lantern Pharma does not pay a dividend.

    How much debt does LTRN have?

    Lantern Pharma has $7.11K of total debt and $7.62M of cash and equivalents, a net cash position of $7.61M.